Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPHI China Pharma	$1.48 +3.5%	$1.69	$1.20 ▼ $3.35	$4.83M	0.87	107,927 shs	6,068 shs
ENSC Ensysce Biosciences	$2.07	$2.16	$1.62 ▼ $14.67	$6.13M	1	884,507 shs	26,627 shs
SLRX Salarius Pharmaceuticals	$5.32 -2.2%	$11.02	$4.76 ▼ $108.00	$770K	0.45	431,513 shs	39,381 shs
VIVS VivoSim Labs	$1.98 +8.2%	$1.77	$1.41 ▼ $21.96	$4.76M	0.94	43,439 shs	78,983 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPHI China Pharma	+1.42%	-3.38%	-18.75%	-35.29%	-92.89%
ENSC Ensysce Biosciences	+1.97%	-3.72%	-4.61%	-4.61%	-66.13%
SLRX Salarius Pharmaceuticals	-3.89%	-25.04%	-50.05%	-53.36%	-82.05%
VIVS VivoSim Labs	+1.67%	-1.61%	-7.58%	+182,999,900.00%	+182,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPHI China Pharma	0.6922 of 5 stars	0.0	5.0	0.0	0.0	1.4	0.8	0.0
ENSC Ensysce Biosciences	0.4395 of 5 stars	0.0	4.0	0.0	0.0	2.2	0.0	0.0
SLRX Salarius Pharmaceuticals	0.1308 of 5 stars	0.0	2.0	0.0	0.0	2.0	0.0	0.0
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPHI China Pharma	N/A	N/A	N/A
ENSC Ensysce Biosciences	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPHI China Pharma	$4.40M	1.10	N/A	N/A	$0.70 per share	2.11
ENSC Ensysce Biosciences	$5.21M	1.18	N/A	N/A	$1.03 per share	2.01
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	($5.85) per share	N/A
VIVS VivoSim Labs	$140K	36.77	N/A	N/A	$3.67 per share	0.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPHI China Pharma	-$3.08M	N/A	0.00	∞	N/A	-85.56%	-63.93%	-31.42%	N/A
ENSC Ensysce Biosciences	-$7.99M	-$4.03	N/A	N/A	N/A	-88.76%	-167.23%	-104.59%	N/A
SLRX Salarius Pharmaceuticals	-$5.58M	-$2.90	N/A	∞	N/A	N/A	-556.47%	-192.35%	N/A
VIVS VivoSim Labs	-$2.48M	-$10.20	N/A	∞	N/A	-1,396.48%	-32.95%	-21.31%	N/A

Latest SLRX, ENSC, VIVS, and CPHI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ENSC Ensysce Biosciences	-$1.02	-$0.79	+$0.23	-$0.79	$0.67 million	$1.37 million
8/12/2025	Q2 2025	SLRX Salarius Pharmaceuticals	-$33.00	-$0.45	+$32.55	-$0.45	N/A	N/A
8/12/2025	Q1 2026	VIVS VivoSim Labs	N/A	-$1.14	N/A	-$1.14	N/A	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
ENSC Ensysce Biosciences	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPHI China Pharma	0.22	0.79	0.26
ENSC Ensysce Biosciences	N/A	2.10	2.10
SLRX Salarius Pharmaceuticals	N/A	0.61	0.61
VIVS VivoSim Labs	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPHI China Pharma	N/A
ENSC Ensysce Biosciences	5.63%
SLRX Salarius Pharmaceuticals	11.88%
VIVS VivoSim Labs	8.23%

Insider Ownership

Company	Insider Ownership
CPHI China Pharma	17.32%
ENSC Ensysce Biosciences	7.90%
SLRX Salarius Pharmaceuticals	1.20%
VIVS VivoSim Labs	3.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPHI China Pharma	250	3.26 million	15.92 million	Not Optionable
ENSC Ensysce Biosciences	10	2.97 million	2.73 million	Not Optionable
SLRX Salarius Pharmaceuticals	20	140,000	140,000	Not Optionable
VIVS VivoSim Labs	20	2.60 million	2.50 million	N/A

SLRX, ENSC, VIVS, and CPHI Headlines

Recent News About These Companies

VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | finanznachrichten.de

VivoSim appoints Lialin as Chief Commercial Officer

August 14, 2025 | msn.com

VivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer to Drive Growth in 3D Drug Testing Services

August 14, 2025 | quiverquant.comQ

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | financialpost.comF

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | globenewswire.com

VivoSim: Fiscal Q1 Earnings Snapshot

August 12, 2025 | timesunion.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRX, ENSC, VIVS, and CPHI Company Descriptions

China Pharma NYSE:CPHI

$1.48 +0.05 (+3.50%)

Closing price 03:59 PM Eastern

Extended Trading

$1.46 -0.02 (-1.69%)

As of 07:10 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Ensysce Biosciences NASDAQ:ENSC

$2.07 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.08 +0.01 (+0.24%)

As of 07:48 PM Eastern

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Salarius Pharmaceuticals NASDAQ:SLRX

$5.32 -0.12 (-2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$5.26 -0.06 (-1.15%)

As of 07:50 PM Eastern

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

VivoSim Labs NASDAQ:VIVS

$1.98 +0.15 (+8.20%)

As of 04:00 PM Eastern

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time